Literature DB >> 22522292

Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study.

M L Moro1, E Grilli, A Corvetta, G Silvi, R Angelini, F Mascella, F Miserocchi, P Sambo, A C Finarelli, V Sambri, C Gagliotti, E Massimiliani, A Mattivi, A M Pierro, P Macini.   

Abstract

OBJECTIVES: Following a Chikungunya (CHIKV) outbreak in Italy, a cohort study was conducted to describe the infection long-term clinical course and outcome.
METHODS: Persons identified through active and passive surveillance as confirmed or possible CHIKV cases during the outbreak were enrolled and interviewed by trained public health nurses, between 4-5 and 12-13 months following the acute stage. Patients reporting persistent clinical symptoms were evaluated by rheumatologists. Serum samples were obtained and anti-CHIKV specific IgG and IgM immune responses detected. Only confirmed cases who completed the follow-up were analysed.
RESULTS: Out of 250 patients, 66.5% still reported myalgia, asthenia or arthralgia (most frequent sign) after 12 months. Functional ability, measured by the ROAD index, was more impaired for lower extremities (3.75; Inter Quartile Range - IQR 4.4), and the activities of daily living (average 4.2; IQR 5). Variables independently associated with the presence of joint pain at 12-13 months were increasing age, and history of rheumatologic diseases). Elderly, females, and persons with history of rheumatologic diseases had higher anti-CHIKV IgG titres at 12-13 months.
CONCLUSIONS: This study confirms, in an unselected population, that the long-lasting burden of CHIKV infection is significant.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522292     DOI: 10.1016/j.jinf.2012.04.005

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  45 in total

1.  Chikungunya Virus Disease among Travelers-United States, 2014-2016.

Authors:  Nicole P Lindsey; J Erin Staples; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2018-01-01       Impact factor: 2.345

2.  Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.

Authors:  Ryan M Kramer; Yuhong Zeng; Neha Sahni; Lisa A Kueltzo; Richard M Schwartz; Indresh K Srivastava; Lindsey Crane; Sangeeta B Joshi; David B Volkin; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2013-10-15       Impact factor: 3.534

3.  Occurrence of Chronic Stage Chikungunya in the General Population of Martinique during the First 2014 Epidemic: A Prospective Epidemiological Study.

Authors:  Brieg Couzigou; Anne Criquet-Hayot; Emilie Javelle; Sandrine Tignac; Edith Mota; François Rigaud; Alizé Alain; Odile Troisgros; Sandrine Pierre-Francois; Sylvie Abel; Rishika Banydeen; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2018-05-24       Impact factor: 2.345

4.  Chikungunya fever in Africa: a systematic review.

Authors:  Gianluca Russo; Lorenzo Subissi; Giovanni Rezza
Journal:  Pathog Glob Health       Date:  2020-04-18       Impact factor: 2.894

Review 5.  Viral arthritis.

Authors:  Michael Marks; Jonathan L Marks
Journal:  Clin Med (Lond)       Date:  2016-04       Impact factor: 2.659

6.  Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Authors:  David W Hawman; Kristina A Stoermer; Stephanie A Montgomery; Pankaj Pal; Lauren Oko; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

7.  Seroprevalence and Symptomatic Attack Rate of Chikungunya Virus Infection, United States Virgin Islands, 2014-2015.

Authors:  Morgan J Hennessey; Esther M Ellis; Mark J Delorey; Amanda J Panella; Olga I Kosoy; Hannah L Kirking; Grace D Appiah; Jin Qin; Alison J Basile; Leora R Feldstein; Brad J Biggerstaff; Robert S Lanciotti; Marc Fischer; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

8.  Post-Chikungunya Virus Infection Musculoskeletal Disorders: Syndromic Sequelae after an Outbreak.

Authors:  Hisham A Imad; Wasin Matsee; Sajikapon Kludkleeb; Punyisa Asawapaithulsert; Juthamas Phadungsombat; Emi E Nakayama; Keita Suzuki; Pornsawan Leaungwutiwong; Watcharapong Piyaphanee; Weerapong Phumratanaprapin; Tatsuo Shioda
Journal:  Trop Med Infect Dis       Date:  2021-04-15

9.  Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study.

Authors:  Patrick Gérardin; Adrian Fianu; Alain Michault; Corinne Mussard; Karim Boussaïd; Olivier Rollot; Philippe Grivard; Somar Kassab; Eric Bouquillard; Gianandrea Borgherini; Bernard-Alex Gaüzère; Denis Malvy; Gérard Bréart; François Favier
Journal:  Arthritis Res Ther       Date:  2013-01-09       Impact factor: 5.156

10.  Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study.

Authors:  Clémentine Schilte; Frederik Staikowsky; Frédérik Staikovsky; Thérèse Couderc; Yoann Madec; Florence Carpentier; Somar Kassab; Matthew L Albert; Marc Lecuit; Alain Michault
Journal:  PLoS Negl Trop Dis       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.